Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | PTAFR | P25105 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10824976 | 0.89 | ADRA1D (0.55) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL8435468 | 0.89 | ADRA1D (0.55) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL8438758 | 0.89 | ADRA1D (0.55) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL10894210 | 0.89 | ADRA1D (0.55) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| Cetyl Alcohol SCHEMBL8600510 | 0.87 | PRKCA (0.60) | PRKCAALDH1A1LMNA | |
| Cetostearyl Alcohol SCHEMBL27687492 | 0.87 | PRKCA (0.60) | PRKCAALDH1A1LMNA | |
| SCHEMBL5025539 | 0.86 | ADRA1D (0.44) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL14036738 | 0.86 | ADRA1D (0.44) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| Triacetin SCHEMBL17821531 | 0.85 | PRKCA (0.55) | PRKCAADRA1DPTAFRHTR1DHTR2C | |
| SCHEMBL13449715 | 0.85 | ALDH1A1 (0.53) | PRKCAADRA1DPTAFRHTR1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465876-B1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1465876-B1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-20040266747-A1 | Long chain fatty alcohol substituents in antineoplastic agents | PFAENDLER HANS R (DE) | 2004-12-30 | — | — | US | disclosed |
| EP-1465876-A1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | Pfaendler, Hans Rudolf (DE) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003055864-A1 | LONG CHAIN FATTY ALCOHOL SUBSTITUENTS IN ANTINEOPLASTIC AGENTS | PFAENDLER HANS RUDOLF (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266747-A1 | Long chain fatty alcohol substituents in antineoplastic agents | FASN, ELOVL3, ELOVL1 | PRKCA 2414/4885ADRA1D 1150/4885PTAFR 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.